Abramson Cancer Center hematologic malignancies’ clinicians and researchers have led the way nationally for years; both in the care of patients with hematologic malignancies (blood cancer) and in its research.
Today, there's more hope than ever for those who face a blood cancer diagnosis.
Penn’s program is one of the oldest and largest in the country. By putting our experience to work, we offer the best possible treatment outcomes.
Penn has one of the few Hematologic Malignancy (leukemia, lymphoma and myeloma) Research Programs in the country that is approved and funded by the National Cancer Institute. It is through this research program that Penn has made significant advances in improving bone marrow and stem cell transplants and the care of patients with blood cancer.
The knowledge gained through our research allows us to better care for those with blood cancers.
To learn about what sets us apart, visit:
Suzi F. Garber, of Reading, PA., a neuroendocrine tumor patient at the Abramson Cancer Center, writes about her experience so that others might benefit from her story and become proactive advocates for themselves and their loved ones.
For many years, I had been misdiagnosed as having irritable bowel syndrome. After I wound up in the emergency ward in intense pain, I had a battery of tests -- I had an ileal bowel obstruction. An octreotide scan showed spots in my liver which was subsequently biopsied and were positive for carcinoid cancer, Stage IV. I had been diagnosed with a rare cancer that both had metastasized and was inoperable at the time.
Focus On Blood Cancers and Bone Marrow Transplant Video
A patient education video with testimonies from our patients, doctors and researchers. Find out more about programs, treatment, research and care that is unique to the Abramson Cancer Center.